NextCure, Inc. (NXTC)

NASDAQ: NXTC · IEX Real-Time Price · USD
1.29
0.00 (0.00%)
Sep 29, 2023, 4:00 PM EDT - Market closed
Market Cap 35.91M
Revenue (ttm) n/a
Net Income (ttm) -70.17M
Shares Out 27.84M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,447
Open 1.31
Previous Close 1.29
Day's Range 1.28 - 1.34
52-Week Range 1.16 - 3.17
Beta 0.08
Analysts Strong Buy
Price Target 6.33 (+390.7%)
Earnings Date Nov 2, 2023

About NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preser... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 99
Stock Exchange NASDAQ
Ticker Symbol NXTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for NXTC stock is "Strong Buy." The 12-month stock price forecast is $6.33, which is an increase of 390.70% from the latest price.

Price Target
$6.33
(390.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease

BELTSVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

4 days ago - GlobeNewsWire

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

• Data presented at the 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore

19 days ago - GlobeNewsWire

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

23 days ago - GlobeNewsWire

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

BELTSVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

25 days ago - GlobeNewsWire

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

4 weeks ago - GlobeNewsWire

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

BELTSVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

2 months ago - GlobeNewsWire

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

3 months ago - GlobeNewsWire

NextCure to Present at the JMP Securities Life Sciences Conference

BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine...

5 months ago - GlobeNewsWire

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

BELTSVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) --  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

5 months ago - GlobeNewsWire

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

6 months ago - GlobeNewsWire

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

7 months ago - GlobeNewsWire

NextCure to Present at SVB Securities Global Biopharma Conference

BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

8 months ago - GlobeNewsWire

NextCure to Present at Upcoming Investor Conferences

BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

11 months ago - GlobeNewsWire

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

BELTSVILLE, Md. and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-de...

11 months ago - GlobeNewsWire

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

11 months ago - GlobeNewsWire

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

11 months ago - GlobeNewsWire

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

11 months ago - GlobeNewsWire

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Oct. 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

BELTSVILLE, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

1 year ago - GlobeNewsWire

NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

BELTSVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation

BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire

NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc.  (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici...

1 year ago - GlobeNewsWire

Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua

BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin...

1 year ago - GlobeNewsWire